Study details
Enrolling now
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co., Ltd.
NCT IDNCT06266299ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
71
Study length
about 4 years
Ages
18+
Locations
7 sites in AZ, CA, FL +3
About this study
Researchers are testing a new drug called KK2269 to see if it's safe and well-tolerated. The trial will involve adults with advanced or metastatic solid tumors for which no standard therapy is available. It is also investigating the safety of KK2269 when combined with docetaxel in patients who have already received other treatments.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Docetaxel
- 2.Take KK2269
PhasePhase 1
DrugDocetaxel
Routeinfusion
Primary goalNumber of Adverse Events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
docetaxel
Drug routes
infusion
Endpoints
Primary: Number of Adverse Events, Number of Subjects Experiencing Dose-limiting Toxicity
Body systems
Oncology